Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares advanced around 11% after announcing the signing of a letter of intent with Cellin Technologies, to explore the commercialisation of its HG-CT-1 CAR-T therapy in Estonia.
The therapy targets relapsed or refractory acute myeloid leukaemia.
The agreement will use Estonia’s hospital exemption pathway, which permits the use of advanced therapies ahead of full commercial approval, provided sufficient trial data is available.
Hemogenyx will retain all intellectual property and receive revenues from commercialisation, while Cellin will provide regulatory and operational support.
"The partnership with Cellin creates a path to generate initial revenues from HG-CT-1 under Estonia's hospital exemption pathway, while providing valuable real-world patient data to complement our Phase I trial and support the future development and commercialization of the therapy," said chief executive Dr Vladislav Sandler.
In London, Hemogenyx shares climbed around 11% changing hands at 1,600p, valuing the business at over £86 million, which means the share is up some 755% over the past month.